SCHEMBL410177

SCHEMBL410177

Cc1cc(C#N)ccc1CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.41
ALDH1A1 P00352 1/20 0.41
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
FFAR1 O14842 2/20 0.39
FFAR4 Q5NUL3 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.38
CA12 O43570 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37
CA6 P23280 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
AR P10275 5/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SETDB1 Q15047 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8028511 0.87 HRH2 (0.42) AR
SCHEMBL3997043 0.85 MMP3 (0.46) CYP2A6ALDH1A1AR
SCHEMBL12226952 0.85 FFAR1 (0.40) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL8436238 0.84 CYP2A6 (0.41) CYP2A6ALDH1A1FFAR1FFAR4CA12
SCHEMBL2154771 0.83 CYP2A6 (0.44) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL2153680 0.83 CYP2A6 (0.44) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL12763619 0.82 CYP2A6 (0.48) CYP2A6ALDH1A1KDM5AKDM4CKDM5B
SCHEMBL5446462 0.81 XDH (0.46) ALDH1A1AR
SCHEMBL13608787 0.81 CA2 (0.41) CYP2A6ALDH1A1CA12CA2CA3
SCHEMBL3715551 0.80 CYP2A6 (0.41) CYP2A6ALDH1A1KDM5AKDM4CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-05-09 US disclosed
CN-117466882-A Compounds as modulators of the S1P receptor and uses thereof 华东师范大学 2024-01-30 CN disclosed
CN-114805341-B Aromatic heterocyclic compound, and preparation method and application thereof 上海翊石医药科技有限公司 2023-12-08 CN disclosed
WO-2022161420-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2022-08-04 WO disclosed
WO-2022161420-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2022-08-04 WO disclosed
CN-114805341-A Aromatic heterocyclic compounds and preparation method and application thereof 上海翊石医药科技有限公司 2022-07-29 CN disclosed
EP-3763367-A1 PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2021-01-13 EP disclosed
EP-3763367-A1 PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2021-01-13 EP disclosed
EP-2928471-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-10-14 EP disclosed
EP-2928471-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-10-14 EP disclosed
US-20120022109-A1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2012-01-26 US disclosed
WO-2010115751-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-14 WO disclosed
WO-2010112461-A1 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-07 WO disclosed
CN-100379722-C Compounds ASTRA ZENECA LTD (SE) 2008-04-09 CN disclosed
EP-1036061-B1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2003-09-24 EP disclosed
US-6337394-B2 N-ACYL-HETEROCYCLE-CARBOXYAMIDES THAT ARE N-SUBSTITUTED WITH AMIDINO-SUBSTITUTED RINGS; COMPETITIVE INHIBITORS OF THROMBIN; ANTICOAGULANTS ASTRAZENECA AB (SE) 2002-01-08 US disclosed
US-20010046981-A1 COMPOUNDS ASTRA AKTIEBOLAG (SE) 2001-11-29 US disclosed
CN-1284063-A Compounds ASTRA ZENECA LTD (SE) 2001-02-14 CN disclosed
EP-1036061-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2000-09-20 EP disclosed
WO-1999029664-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF TLR7, TLR1, TLR8 CYP2A6 621/4885ALDH1A1 1289/4885KDM5A 3781/4885
US-20010046981-A1 COMPOUNDS F2, SERPINC1, SERPINB1 CYP2A6 1226/4885ALDH1A1 2984/4885KDM5A 4076/4885
US-20120022109-A1 OXADIAZOLE DERIVATIVES OXA1L, HLA-DRB1, SSB CYP2A6 2143/4885ALDH1A1 510/4885KDM5A 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.